Specifically, Defendants made false and / or misleading statements and / or failed to disclose that: (i) Akorn's failure to comply with FDA data integrity requirements would jeopardize Fresenius» acquisition of Akorn; (ii) the Company lacked effective internal controls over financial reporting; and (iii) as a result of the foregoing, Akorn shares
traded at artificially inflated prices
during the
Class Period, and class members suffered significant losses and dam
Class Period, and
class members suffered significant losses and dam
class members suffered significant losses and damages.
During the
Class Period, Barclays» dark pool catapulted into the financial stratosphere, with market share growth of 33 % per year, as Barclay falsely promised investors that it would police the pool to «protect [clients] from predatory
trading.»